C Terminus of Clostridium perfringens Enterotoxin Downregulates CLDN4 and Sensitizes Ovarian Cancer Cells to Taxol and Carboplatin
- 1 March 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (5), 1065-1074
- https://doi.org/10.1158/1078-0432.ccr-10-1644
Abstract
Purpose: We have previously shown that CLDN4 (encoding claudin-4), a cell tight junction (TJ) protein, is highly expressed in human epithelial ovarian carcinomas (EOC) but undetectable in normal ovaries. CLDN4 has been identified as a specific receptor for C terminus of Clostridium perfringens enterotoxin (C-CPE), a nontoxic molecule that may disrupt TJ barrier function and enhance cellular absorption. The purpose of this study was to determine the potential clinical applications of C-CPE and its effects on CLDN4 expression in EOC. Experimental Design: Using a 3-dimensional culture model and monolayer culture of EOC cells, we examined the effects of C-CPE on CLDN4 expression by quantitative real-time PCR, immunofluorescence, and Western blot. The synergistic effect of C-CPE to clinically relevant chemotherapies (Taxol and Carboplatin) was observed in EOC culture and xenograft mice. Furthermore, we determined through oligonucleotide microarray analysis that the transcript profile alterations dysregulated as a consequence of C-CPE treatment. Results: C-CPE treatment decreased protein expression and relocated CLDN4 from cell–cell contact regions to the cytoplasm. Particularly, C-CPE sensitized EOC cells to chemotherapeutic administration at low dosages and significantly inhibited tumor growth in a nontoxic manner. Furthermore, we provided genome-wide molecular evidence that C-CPE treatment is involved in the stimulation of the ubiquitin–proteasome pathway and the inhibition of cell metabolism in EOC cells. Conclusions: The addition of C-CPE can enhance the effectiveness of Taxol or Carboplatin and significantly inhibited EOC cell growth in a CLDN4-dependent manner, suggesting that C-CPE may have promising therapeutic potential for EOC. Clin Cancer Res; 17(5); 1065–74. ©2010 AACR.Other Versions
This publication has 48 references indexed in Scilit:
- Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptorsMolecular Cancer Therapeutics, 2009
- Clostridium perfringens Enterotoxin as a Novel-Targeted Therapeutic for Brain MetastasisCancer Research, 2007
- Three-dimensional culture models of normal and malignant breast epithelial cellsNature Methods, 2007
- Expression Profiling of Serous Low Malignant Potential, Low-Grade, and High-Grade Tumors of the OvaryCancer Research, 2005
- Claudin Proteins in Human Cancer: Promising New Targets for Diagnosis and TherapyCancer Research, 2005
- Claudin 4 Protein Expression in Primary and Metastatic Pancreatic CancerAmerican Journal of Clinical Pathology, 2004
- Claudin 4 Protein Expression in Primary and Metastatic Pancreatic Cancer Support for Use as a Therapeutic TargetAmerican Journal of Clinical Pathology, 2004
- p53 Tumor Suppressor Protein Content in Human Uterine Leiomyomas and Its Down-Regulation by 17 -EstradiolJournal of Clinical Endocrinology & Metabolism, 2002
- Orientation of spindle axis and distribution of plasma membrane proteins during cell division in polarized MDCKII cells.The Journal of cell biology, 1994